nVerses Capital’s Halozyme HALO Stock Holding History

nVerses Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,700	Closed	-$246K	–	1162
2024 Q2	$246K	Buy	4,700 +2,900	+161%	+$127K	0.15%	226
2024 Q1	$73.2K	Buy	+1,800	New	+$67.5K	0.18%	217

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

nVerses Capital's HALO Position: Q3 2024 in Review

nVerses Capital sold out of Halozyme (HALO) in Q3 2024, closing a stake of 4,700 shares — an estimated $246K sold.

nVerses Capital first reported a position in HALO in Q1 2024 and held it in 2 quarters. The position peaked at $246K in Q2 2024. 508 funds tracked by Wall St. Rank hold HALO as of Q3 2024.

nVerses Capital reported no remaining Halozyme position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 4,700 Halozyme shares in Q3 2024, an estimated $246K.
nVerses Capital first reported a position in Halozyme in Q1 2024 and held it in 2 quarters.
nVerses Capital's Halozyme position peaked at $246K in Q2 2024.
508 funds tracked by Wall St. Rank held Halozyme as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.